Belite Bio, Inc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BLTE | 688759.SS | 688382.SS | B9A.F | MIRM | BHVN | |
|---|---|---|---|---|---|---|
| Market cap | 6.20B | 7.56B | 8.38B | 2.45B | 6.30B | 2.30B |
| P/E (TTM) | — | — | — | 250.7 | — | — |
| Forward P/E | 68.1 | — | -43.8 | — | -570.4 | -8.2 |
| Price/book | 8.0 | 4.9 | 6.6 | 1.2 | 16.0 | -23.4 |
| Dividend yield | — | — | — | 0.68% | — | — |
| 1-year change | +35.36% | −52.52% | −48.70% | +5.23% | +24.17% | +87.17% |
| Today | +1.21% | +4.42% | +4.33% | −0.29% | +11.42% | −2.37% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BLTE news ›Belite Bio (BLTE) Projected to Release Earnings on Monday
Posted by Danessa Lincoln on Nov 2nd, 2026 Belite Bio (NASDAQ:BLTE – Get Free Report) is projected to post its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to post earnings of ($0.7863) per…
Belite Bio Announces Uplisting to the Nasdaq Global Select Market
Belite Bio expects the move to improve liquidity and increase its visibility among institutional investors. Belite Bio (BLTE) received Nasdaq approval to transfer its securities listing from the Nasdaq Capital Market to the Nasdaq Global…
Belite Bio’s (BLTE) “Buy” Rating Reiterated at HC Wainwright
Posted by Tristan Rich on Oct 18th, 2026 HC Wainwright restated their buy rating on shares of Belite Bio (NASDAQ:BLTE – Free Report) in a research report sent to investors on Thursday morning, Marketbeat reports. The firm currently has a…
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
Carroll County Mirror-Democrat - If approved, tinlarebant would be the first-ever approved treatment for Stargardt Dise
Belite Bio: Bioptima sells 500 depositary shares
Belite Bio (NASDAQ: BLTE) is a clinical-stage drug developer focused on oral therapies for Stargardt disease, geographic atrophy in dry AMD, and specific metabolic diseases. - [Form 4] BELITE BIO, INC Insider Trading Activity Belite Bio:…
Belite Bio (NASDAQ:BLTE) Insider Hendrik Peter Scholl Sells 500 Shares of Stock
Posted by Defense World Staff on Oct 6th, 2026 NASDAQ BLTE opened at $159.18 on Tuesday. The business has a fifty day simple moving average of $166.50 and a 200 day simple moving average of $157.74. Belite Bio, Inc. Sponsored ADR has a 12…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net3
- themarketsdaily.com2
- defenseworld.net1
- globenewswire.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.